No Data
Fuyuan Pharmaceutical: Beijing Fuyuan Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Beijing Fuyuan Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Fuyuan Pharmaceutical (601089.SH): Dapagliflozin tablets have obtained the Pharmaceutical registration certificate.
On April 9th, Glonghui announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., received the drug registration certificate issued by the National Medical Products Administration for Dapagliflozin Tablets [Specification 1: 5mg (calculated as C₂₁H₂₅ClO₆); Specification 2: 10mg (calculated as C₂₁H₂₅ClO₆)], hereinafter referred to as "the Pharmaceutical". This product is suitable for adult patients with type 2 diabetes and is not suitable for the treatment of type 1 diabetes or diabetic ketoacidosis.
Fuyuan Pharmaceutical (601089.SH): FY101 injection has received the notice of approval for the clinical trial of the drug.
On April 8th, Gelonghui reported that Fuyuan Pharmaceutical (601089.SH) announced it had received the approved drug clinical trial notification from the National Medical Products Administration for FY101 injection, which will soon begin clinical trials. The FY101 injection is a Class 1 Innovative Drug, a Chemical Drug independently developed by the company, suitable for the treatment of hyperlipidemia, with the administration route being subcutaneous injection. Currently, there are no similar products targeting the same indication approved for market release domestically or internationally. As of now, the total R&D investment for the FY101 injection project is approximately 29.2535 million yuan (unaudited).
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Fuyuan Pharmaceutical: Beijing Fuyuan Pharmaceutical Co., Ltd. Fuyuan Pharmaceutical 2024 Annual Report Summary
